

APC Cynomolgus CD25 (IL-2R α) Protein (C-His)

Catalog Number:	812103, 812104
Size:	25 ug, 100 ug
Target Name:	IL2RA, CD25, p55, IL2-RA, IL-2-RA
Regulatory Status:	RUO

PRODUCT DETAILS

Application:	Flow Cytometry
Format:	Liquid, APC
Expression Host:	CHO
Species:	Cynomolgus monkey
Sources:	Recombinant Cynomolgus CD25 (Glu22-Arg213) with C-terminus His-tag is expressed in CHO cell and conjugated to APC.
Accession Number:	P63309
Molecular Weight:	The protein has a predicted molecular weight of 23.5 kDa. Under DTT-reducing conditions, it migrates at approximately 35 kDa on SDS-PAGE prior to conjugation.
Affinity Tag:	C-His
Formulation:	1xPBS buffer, pH7.4, 0.09% NaN ₃ with a carrier protein
Endotoxin level:	Not tested
Protein Concentration:	25 μ g size is bottled at 0.1mg/mL concentration. 100 μ g size is bottled at lot specific concentration.
Storage and Handling:	Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

BACKGROUND INFORMATION

CD25, also known as the interleukin-2 receptor alpha chain (IL-2R α), is a transmembrane glycoprotein that plays a central role in regulating immune responses. It functions as part of the interleukin-2 (IL-2) receptor complex, which is essential for T cell proliferation, survival, and differentiation. CD25 itself has low affinity for IL-2 when expressed alone, but when combined with IL-2 receptor beta (CD122) and the common gamma chain (CD132), it forms the high-affinity IL-2 receptor complex capable of effective signal transduction.

Structurally, CD25 is a single-pass type I membrane protein composed of an extracellular domain of approximately 219 amino acids responsible for IL-2 binding, a hydrophobic transmembrane segment, and a short cytoplasmic tail that lacks intrinsic signaling domains. The extracellular region is heavily glycosylated, which stabilizes its conformation and facilitates ligand interaction. Because the alpha chain alone is not signaling-competent, it acts primarily to increase the receptor complex's affinity for IL-2 and to expand the range of cells responsive to low cytokine concentrations.

CD25's main ligand, IL-2, is a cytokine crucial for T lymphocyte expansion and immune tolerance. Engagement of IL-2 with the high-affinity receptor triggers the JAK-STAT signaling pathway, leading to cell proliferation, differentiation, and regulatory T cell (Treg) function. CD25 is constitutively expressed on Tregs and upregulated on activated CD4+ and CD8+ T cells, making it a marker of immune activation as well as immune regulation.

Aberrant CD25 expression or IL-2 signaling contributes to immune dysregulation and disease. In autoimmune disorders such as multiple sclerosis and type 1 diabetes, alterations in the IL-2/CD25 axis impair Treg function and tolerance mechanisms. Elevated CD25 expression is also found in certain malignancies, particularly adult T-cell leukemia/lymphoma and Hodgkin lymphoma, where it may serve as a biomarker of malignant proliferation. Moreover, soluble CD25, released from cell surfaces, can act as a decoy receptor, modulating IL-2 availability and contributing to immune suppression in cancer and chronic inflammation.

Therapeutically, CD25 is a prominent target for immune modulation. Monoclonal antibodies such as basiliximab and daclizumab have been developed to block IL-2 binding, preventing T cell activation and mitigating graft rejection in organ transplantation. Conversely, IL-2 or CD25-targeted therapies that enhance regulatory T cell function are being explored to treat autoimmune diseases and promote immune tolerance. Thus, CD25 remains a critical immunological node, balancing activation and regulation within the immune system.

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.